Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06281665 · ClinicalTrials.gov registry record · Phase 4
Treatment With Aspirin After Preeclampsia: TAP Trial
A Phase 4 study of Hypertension and Cardiovascular Diseases, sponsored by Malamo Countouris.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06281665 is a Phase 4 study of Hypertension and Cardiovascular Diseases that is actively recruiting participants, run by Malamo Countouris. The registered enrollment target is 60 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06281665, a Phase 4 study of Hypertension and Cardiovascular Diseases, is actively recruiting participants, sponsored by Malamo Countouris.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low-dose aspirin
Study Locations (1)
Pennsylvania
- University of Pittsburgh Magee-Womens Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-05-29 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06281665
The ClinicalTrials.gov registry entry for NCT06281665 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The listed sponsor is Malamo Countouris, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06281665 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06281665 about?
NCT06281665 is a clinical study titled "Treatment With Aspirin After Preeclampsia: TAP Trial". The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a rando...
What is the current status of trial NCT06281665?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2024-05-29. Estimated completion is 2027-06-01.
What conditions does trial NCT06281665 study?
This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases, Pregnancy Complications, Gestational Hypertension.
What interventions are being tested in trial NCT06281665?
The interventions under investigation include: Placebo (DRUG), Low-dose aspirin (DRUG).
Who is sponsoring clinical trial NCT06281665?
This trial is sponsored by Malamo Countouris, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06281665 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
MR Antagonist and LSD1
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.